FTRE
Fortrea Holdings Inc. · Healthcare · Biotechnology
Last
$10.30
+$0.21 (+2.08%) 1:15 PM ET
Prev close $10.09
Open $10.43
Day high $10.52
Day low $10.16
Volume 307,890
Avg vol 1,293,160
Mkt cap
$943.42M
P/E ratio
-0.95
FY Revenue
$2.72B
EPS
-10.84
Gross Margin
18.50%
Sector
Healthcare
AI report sections
FTRE
Fortrea Holdings Inc.
No AI report section text found yet for this symbol.
Volume vs average
Intraday (cumulative)
−7% (Below avg)
Vol/Avg: 0.93×
RSI
53.69 (Neutral)
Neutral (40–60)
MACD momentum
Intraday
-0.01 (Weak)
MACD: -0.00 Signal: 0.01
Short-Term
+0.19 (Strong)
MACD: -0.19 Signal: -0.38
Long-Term
+0.21 (Strong)
MACD: -1.15 Signal: -1.37
Intraday trend score 46.30

Latest news

FTRE 12 articles Positive: 4 Neutral: 5 Negative: 3
Positive GlobeNewswire Inc. • Fortrea
Fortrea dévoile Fortrea Intelligent Technology™ : une technologie destinée à permettre aux investigateurs et aux centres d’essais cliniques de mener des essais plus intelligents et mieux intégrés

Fortrea, a leading global contract research organization, announced the launch of Fortrea Intelligent Technology (FIT), an AI-powered suite of solutions designed to revolutionize clinical trial processes. FIT automates workflows, streamlines oversight, and improves productivity for investigators, clinical trial centers, and research teams. The platform builds on Fortrea's flagship Xcellerate® platform and incorporates AI and machine learning to analyze complex patterns, generate predictive signals, and reduce manual tasks while enabling faster decision-making and risk management.

FTRE clinical trials AI technology Fortrea Intelligent Technology Xcellerate platform workflow automation risk-based quality management contract research organization
Sentiment note

Fortrea announced a significant product innovation (FIT) that enhances its core offerings with AI-powered solutions. The launch demonstrates technological advancement, expanded capabilities across clinical trial processes, and positions the company competitively in the CRO market. Executive quotes emphasize transformative potential and improved efficiency for clients, indicating strong confidence in the new platform.

Positive GlobeNewswire Inc. • Fortrea
Fortrea 推出 Fortrea Intelligent Technology™,助力申办方和研究中心开展更智能、更协同的临床试验

Fortrea, a leading global clinical research organization, launched Fortrea Intelligent Technology (FIT), an AI-driven solution suite designed to transform clinical trial operations. FIT automates workflows, streamlines oversight, and provides real-time insights to sponsors, research sites, and study teams. Built on the Xcellerate® platform, the solution features three pillars: full lifecycle management, foresight analytics, and AI-powered companion tools to accelerate trial delivery and improve quality.

FTRE clinical trials AI-powered solutions workflow automation Xcellerate platform risk-based quality management clinical development drug development
Sentiment note

Fortrea announced a significant product innovation (FIT) that enhances its core platform capabilities with AI and machine learning. The solution addresses key pain points in clinical trial operations, positions the company as a technology leader in the CRO space, and is expected to drive competitive advantage and customer value. Leadership quotes emphasize transformational impact and responsible AI implementation.

Positive GlobeNewswire Inc. • Fortrea
Fortrea 推出 Fortrea Intelligent Technology™ 以助贊助商及研究中心進行更智能、更整合的試驗

Fortrea, a leading global clinical research organization, announced the launch of Fortrea Intelligent Technology (FIT), an AI-powered solution designed to automate workflows and streamline clinical trial operations. Built on the Xcellerate® platform, FIT offers three pillars: full lifecycle trial management, data-driven foresight analytics, and AI-powered companion tools to improve trial speed, predictability, and quality for sponsors and research sites.

FTRE clinical trials artificial intelligence workflow automation Xcellerate platform clinical research organization risk-based quality management drug development
Sentiment note

Fortrea announced a significant innovation with FIT, an AI-powered platform designed to improve clinical trial operations. The solution addresses key pain points in drug development by automating workflows, enhancing decision-making through data analytics, and improving trial efficiency. Leadership quotes emphasize revolutionary transformation and faster delivery of life-changing therapies, indicating strong confidence in the product's market impact and competitive positioning.

Negative GlobeNewswire Inc. • Grabar Law Office
Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf

Grabar Law Office is investigating potential securities fraud and fiduciary breaches for several publicly traded companies, alleging misleading statements and undisclosed business risks that potentially harmed shareholders.

CYTK FTRE SNPS WBTN securities fraud shareholder investigation fiduciary duties class action lawsuit
Sentiment note

Allegations of overstating revenue projections, cost savings, and business prospects following Labcorp spinoff

Neutral GlobeNewswire Inc. • Fortrea
Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Fortrea announced granting 245,000 restricted stock units (RSUs) to two newly hired employees, with vesting occurring in three equal annual installments starting December 10, 2026.

FTRE RSUs inducement award stock units employee compensation
Sentiment note

The announcement is a standard corporate action of granting RSUs to new employees, indicating normal business operations without significant positive or negative implications

Negative GlobeNewswire Inc. • Joshua H. Grabar
Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Unicycive Therapeutics, Inc. (NASDAQ: UNCY); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office is Investigating Claims on Your Behalf

Grabar Law Office is investigating potential securities fraud and fiduciary duty breaches for several publicly traded companies, alleging misleading statements and incomplete disclosures that potentially harmed shareholders.

CYTK FTRE UNCY WBTN securities fraud shareholder investigation fiduciary duty class action lawsuit
Sentiment note

Allegations of overstating revenue projections, cost savings, and business prospects post-spin-off

Positive GlobeNewswire Inc. • Fortrea
Fortrea Completes $75.7 Million Senior Notes Tender Offer Utilizing Cash on Hand

Fortrea has completed a debt tender offer, purchasing $75.7 million of its outstanding 7.500% Senior Secured Notes due 2030, reducing the principal outstanding from $570 million to $494.3 million.

FTRE debt tender offer capital structure senior secured notes financial management
Sentiment note

The company successfully reduced its debt, reinforced its balance sheet strength, and demonstrated disciplined financial management by using cash on hand to fund the tender offer

Negative GlobeNewswire Inc. • Grabar Law Office
Important Notice to Long-Term Shareholders of Avantor, Inc. (NYSE: AVTR); enCore Energy Corp. (NASDAQ: EU); Fortrea Holdings, Inc. (NASDAQ: FTRE); and Stride, Inc. (NYSE: LRN): Grabar Law Office Investigates Claims on Your Behalf

Law firm Grabar Law Office is investigating potential securities fraud and fiduciary duty breaches for four publicly traded companies, alleging misleading statements and undisclosed material facts that impacted investor interests.

AVTR EU FTRE LRN shareholder investigation securities fraud fiduciary duty class action
Sentiment note

Claims of overestimating revenue, overstating cost savings, and inflating EBITDA targets

Neutral GlobeNewswire Inc. • Tracy Krumme
Fortrea Announces Date for Third Quarter 2025 Financial Results and Conference Call

Fortrea, a global contract research organization, will release its third quarter 2025 financial results on November 5, 2025, with a conference call scheduled at 8:00 am ET to review the results and conduct a Q&A session.

FTRE financial results earnings call contract research organization clinical development
Sentiment note

The article is a standard financial results announcement without indicating positive or negative performance, presenting routine corporate communication about an upcoming earnings call

Neutral GlobeNewswire Inc. • Fortrea
Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Fortrea announced granting 75,000 restricted stock units (RSUs) to a newly hired employee, with vesting occurring in three equal annual installments starting September 12, 2026.

FTRE RSUs inducement award stock grant new employee
Sentiment note

The announcement is a standard corporate action of granting stock units to a new employee, which does not inherently suggest positive or negative market implications

Neutral The Motley Fool • Jesterai
Fortrea (FTRE) Q2 Revenue Jumps 7%

Fortrea Holdings reported Q2 2025 revenue of $710.3 million, beating analyst estimates by 12.5%. Despite positive revenue growth and improved adjusted earnings, the company faced challenges including a significant goodwill impairment and a book-to-bill ratio below target.

FTRE clinical trials contract research pharmaceutical services earnings report goodwill impairment
Sentiment note

Mixed financial performance with revenue growth and improved adjusted earnings, offset by goodwill impairment, reduced cash reserves, and below-target book-to-bill ratio

Neutral GlobeNewswire Inc. • Fortrea Holdings Inc.
Fortrea Reports Second Quarter 2025 Results

Fortrea reported Q2 2025 revenues of $710.3 million, with a GAAP net loss of $374.9 million, primarily due to a non-cash goodwill impairment charge. The company raised its 2025 revenue guidance and welcomed new CEO Anshul Thakral.

FTRE contract research organization clinical development financial results goodwill impairment CEO transition
Sentiment note

Mixed financial performance with revenue growth and raised guidance, offset by significant goodwill impairment and net loss, indicating ongoing business challenges and restructuring

News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal